Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rehabilitation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | rehabilitation |
| 2 | NO_INTERVENTION | controls |
| Name | Type | Description |
|---|---|---|
| rehabilitation | OTHER | Nursing consultations and physical training |
Inclusion Criteria: * In-patients at Copenhagen University Hospital who just received an ICD for the first time. Exclusion Criteria: * Patients who: * do not understand the instructions, * are under 18 years old, * are diagnosed with a mental disease, * suffer from a competing disease, ...
Rehabilitation is being studied for its effect on quality of life in patients living with an implantable cardioverter defibrillator. A Phase 2 clinical trial evaluated this use in a population of 196 participants in Denmark. The study has been completed.
Rehabilitation is being developed by Novo Nordisk A/S, a company listed on the stock exchange under the ticker NVO. The company sponsored a Phase 2 clinical trial to investigate the intervention's impact on quality of life in patients with an implantable cardioverter defibrillator.
Rehabilitation is in Phase 2 of clinical development. A Phase 2 trial, identified as NCT00569478, has been completed. This trial enrolled 196 participants and was conducted in Denmark, focusing on quality of life outcomes in patients with an implantable cardioverter defibrillator.
Rehabilitation has one completed clinical trial, NCT00569478, titled "The Effect of Rehabilitation for Patients Living With an Implantable Cardioverter Defibrillator." This Phase 2 study enrolled 196 adults aged 18 years and older in Denmark. The trial was active-controlled and not double-blinded.
Rehabilitation is an investigational intervention and is not approved by the FDA. It is currently in clinical development, with a completed Phase 2 trial evaluating its effect on quality of life in patients with an implantable cardioverter defibrillator. Further regulatory review would be required for approval.